KRAS and neoplasm: Mutant KRas is principally thought to drive precocious mitogenic signaling but is also credited with reprogramming tumor cell metabolism (Kimmelman, 2015), suppressing apoptosis (Cox and Der, 2003, Kauffmann-Zeh et al., 1997) and promoting migration, metastasis (Campbell and Der, 2004), angiogenesis (Kranenburg et al., 2004, Sparmann and Bar-Sagi, 2004), and inflammation (Karin, 2005)—the latter two presumably by indirect signaling, since oncogenic Ras is confined to the epithelial tumor cell compartment.